Showing 2421-2430 of 5065 results for "".
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/videos/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Sleep Disturbances and Psychological Burden of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/sleep-disturbances-and-psychological-burden-of-prurigo-nodularis/37182/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses the impact of itch from prurigo nodularis on quality of life through sleep disturbances and mental health effects.Sleep Disturbances and Psychological Burden of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/sleep-disturbances-and-psychological-burden-of-prurigo-nodularis/48790/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses the impact of itch from prurigo nodularis on quality of life through sleep disturbances and mental health effects.SARS-CoV-2 and the Skin: Inside the COVID-19 Dermatology Registry
https://practicaldermatology.com/conferences/aad-2021/sars-cov-2-and-the-skin-inside-the-covid-19-dermatology-registry/19921/From COVID Toes to COVID Arms, dermatologic manifestations of SARS-CoV-2 infection and COVID-19 vaccination abound. Esther Freeman, MD, PhD, Director of the COVID-19 Dermatology Registry provides an overview of findings and shares information about the relatively new vaccine registry.Diagnostic Approach for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/diagnostic-approach-for-prurigo-nodularis/37137/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, describes his diagnostic algorithm for prurigo nodularis.Nonsurgical Skin Tightening and Facelifts
https://practicaldermatology.com/videos/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/54266/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.IL-31’s Role in Prurigo Nodularis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.Noah Worcester 2024: Dr. Green and Dr. Weinstein on Medicare
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-green-and-dr-weinstein-medicare/24582/Noah Worcester 2024: Dr. Green and Dr. Weinstein on MedicareDermwireTV — Sun Rises, ICD-10 is Delayed…Again
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-sun-rises-icd-10-is-delayed-again/19139/In this week's DermwireTV, Sun acquires Ranbaxy, ICD-10 gets unexpectedly delayed, and Murad Alam recaps the ASLMS conference.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.